RhumbLine Advisers
INMB icon

RhumbLine Advisers’s INmune Bio INMB Stock Holding History

RhumbLine Advisers’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.2K Sell
8,741
-10,871
-55% -$15K ﹤0.01% 3856
2026
Q1 		$22.2K Sell
19,612
-7,915
-29% -$11.3K ﹤0.01% 3710
2025
Q4 		$42.9K Buy
27,527
+4,878
+22% +$8.7K ﹤0.01% 3659
2025
Q3 		$46.9K Buy
22,649
+313
+1% +$716 ﹤0.01% 3670
2025
Q2 		$51.6K Buy
22,336
+3,183
+17% +$23.4K ﹤0.01% 3665
2025
Q1 		$150K Buy
19,153
+2,409
+14% +$19.1K ﹤0.01% 3250
2024
Q4 		$78.2K Buy
16,744
+2,424
+17% +$12.6K ﹤0.01% 3545
2024
Q3 		$77.2K Buy
14,320
+547
+4% +$3.89K ﹤0.01% 3584
2024
Q2 		$121K Buy
+13,773
New +$136K ﹤0.01% 3457

Other funds holding INMB

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

RhumbLine Advisers's INMB Position: Q2 2026 in Review

RhumbLine Advisers reduced its INmune Bio (INMB) stake by 55% in Q2 2026, selling an estimated $15K and leaving 8,741 shares worth $14.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3856.

RhumbLine Advisers first reported a position in INMB in Q2 2024 and has held it in 9 quarters since. The position peaked at $150K in Q1 2025. 82 funds tracked by Wall St. Rank hold INMB as of Q2 2026.

  • RhumbLine Advisers held 8,741 shares of INmune Bio worth $14.2K as of Q2 2026.
  • RhumbLine Advisers sold 10,871 INmune Bio shares in Q2 2026, an estimated $15K.
  • INmune Bio made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3856 holding.
  • RhumbLine Advisers first reported a position in INmune Bio in Q2 2024 and has held it in 9 quarters since.
  • RhumbLine Advisers's INmune Bio position peaked at $150K in Q1 2025.
  • 82 funds tracked by Wall St. Rank held INmune Bio as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.